Figure 6 - uploaded by Maria Stanca
Content may be subject to copyright.
Comparative horizontal attenuated total reflectance (HATR)-FT-IR spectra of MCM-41/cefotaxime, MCM-41/APS-cefotaxime, and MCM-41/APS/GA-cefotaxime (the final 3 cefotaxime-loaded materials used for the desorption experiments). The comparative FT-IR and Raman spectra of MCM-41, MCM-41/APS, and MCM-41/APS/GA confirm the presence of the saturated chain of GA due to the presence of absorption bands centered at 2929 and 2871 cm −1 , respectively, in Figure 7; and 2925 and 2913 cm −1 , respectively, in Figure 8. The absorption bands centered at 2935 and 2878 cm −1 , respectively, in Figure 7; and 2918 and 2892 cm −1 , respectively, in Figure 8, confirm the presence of APS-saturated chains; while the -NH2 groups can be observed at 3361 and 3290 cm −1 , respectively, in Figure 7; and 3369 and 3310 cm −1 , respectively, in Figure 8 (correlated to the presence of the peak corresponding to nitrogen in the EDS spectrum Figure 2 and T 3 peak from MAS-NMR Figure 5). Moreover, the intensity of the characteristic bands of -NH2 groups from the MCM-41/APS/GA significantly decreased in comparison to the mesoporous silica-amino groups.

Comparative horizontal attenuated total reflectance (HATR)-FT-IR spectra of MCM-41/cefotaxime, MCM-41/APS-cefotaxime, and MCM-41/APS/GA-cefotaxime (the final 3 cefotaxime-loaded materials used for the desorption experiments). The comparative FT-IR and Raman spectra of MCM-41, MCM-41/APS, and MCM-41/APS/GA confirm the presence of the saturated chain of GA due to the presence of absorption bands centered at 2929 and 2871 cm −1 , respectively, in Figure 7; and 2925 and 2913 cm −1 , respectively, in Figure 8. The absorption bands centered at 2935 and 2878 cm −1 , respectively, in Figure 7; and 2918 and 2892 cm −1 , respectively, in Figure 8, confirm the presence of APS-saturated chains; while the -NH2 groups can be observed at 3361 and 3290 cm −1 , respectively, in Figure 7; and 3369 and 3310 cm −1 , respectively, in Figure 8 (correlated to the presence of the peak corresponding to nitrogen in the EDS spectrum Figure 2 and T 3 peak from MAS-NMR Figure 5). Moreover, the intensity of the characteristic bands of -NH2 groups from the MCM-41/APS/GA significantly decreased in comparison to the mesoporous silica-amino groups.

Source publication
Article
Full-text available
As a third-generation β-lactam antibiotic, cefotaxime shows a broad-spectrum with Gram-positive and Gram-negative bacteria activity and is included in WHO’s essential drug list. In order to obtain new materials with sustained release properties, the present research focuses on the study of cefotaxime absorption and desorption from different functio...

Citations

... As a result, we found that the scaffold we developed released the antibiotic more slowly and for a longer duration. It is thought that a bioeliminable scaffold that offers controlled and slow drug release may be more effective on biofilm and more successful in the treatment of osteomyelitis [27]. ...
Article
Full-text available
Background Local antibiotic applications have been used in chronic osteomyelitis and have been defined as an adjunctive treatment method. Biodegradable materials are also used for the same purpose by adding antibiotics. The fact that it does not require additional surgery to be removed is an important advantage. In this study, we intended to develop a new biodegradable drug-loaded polymeric scaffold with good antibiotic release and compare the microbiological results with antibiotic-impregnated bone cement. Methodology A tissue scaffold containing poly(2-hydroxyethyl methacrylate) (PHEMA) was prepared in our laboratory and loaded with ertapenem and daptomycin antibiotics. The surface morphology and pore geometries of drug-loaded and unloaded scaffolds were analyzed by a scanning electron microscope under vacuum. The dose-dependent antiproliferative effects of PHEMA scaffold, drug-loaded scaffold, cement, and drug-loaded cement on osteoblast cells were investigated. To evaluate drug release kinetics, the absorbance values of the scaffold loaded with ertapenem and daptomycin were measured with the spectrometer. For microbiological tests, ertapenem and daptomycin-impregnated cement and scaffold, as well as the control scaffold and cement samples, were investigated for their antibacterial activities on Staphylococcus aureus and Klebsiella pneumoniae strains using the disc diffusion method. These microorganisms are one of the most common microorganisms in osteomyelitis. Results The efficacy of antibiotic-impregnated scaffold and cement on both gram-negative and gram-positive microorganisms was investigated. The daptomycin zone diameter in S. aureus ATCC 29233 strain was 17 mm, whereas it was 24 mm for scaffold and 22 mm for cement. Scaffold was found to be more effective than cement against S. aureus strain. The K. pneumoniae ATCC BAA-2814 strain was found to be resistant to ertapenem, but the zone diameter was 21 mm for scaffold and 20 mm for cement. Ertapenem-loaded scaffold was found to be more effective than cement. It was found that the antimicrobial activity of the scaffold was higher than cement. When we evaluated the release profiles, for the daptomycin-loaded cement group, 98% of daptomycin was cumulatively released within 30 minutes, and for the daptomycin-loaded scaffold group, 100% of daptomycin was cumulatively released in six days. To compare ertapenem-loaded cement and scaffold, 98% of ertapenem was cumulatively released within 10 minutes in the cement group. For the scaffold group, 100% of ertapenem was cumulatively released in 17 days. We found that the scaffold released the antibiotic more slowly and for a longer duration. Therefore, it was thought that the scaffold would be more effective on biofilm and the treatment of osteomyelitis would be more successful. Conclusions The produced scaffold was compared with cement, and it was concluded that the scaffold had better release and antimicrobial efficacy. Scaffold is more advantageous than cement because it is bioeliminable. Thus, there is no need for a second surgical intervention with the likely prevention of mortality and morbidity. Because of all these features, the scaffold seems promising in the local treatment of osteomyelitis.
... The slow-release profiles were obtained by using an on-flow modified HPLC system. A significant improved release capacity was identified in the case of MCM-41/APS/GA-cefotaxime due to the covalent surface grafting of the biological active compound, recommending this class of materials as an effective carrier of bioactive compounds in wound dressing, anti-biofilm coatings, advanced drugs, and other related applications [4]. ...
Article
Full-text available
Organogels, hydrogels, and ionic gels are investigated both theoretically and experimentally [...]
Article
Clindamycin is an antibiotic used to treat a variety of bacterial infections. The sustained release of clindamycin from the drug carrier is an important strategy to prolong the effective antibacterial duration. In this work, the microstructure and dynamics of clindamycin confined into the nanopores of mesopore silica with different pore sizes were studied using molecular dynamics simulation. It is found that there is a layering behavior for clindamycin distribution as a function of distance from the pore surface to the pore center with preferred location near the surface of the nanopore. The radial distribution function between carbonyl oxygen and the silanol groups shows the highest intensity of the first peak with the preferred orientation of carbonyl oxygen pointing toward the pore surface, which suggests the strong interaction between the carbonyl oxygen and the silanol groups on the pore surface. The higher local diffusion coefficients for the clindamycin molecules near the pore surface can be found. In addition, the presence of water can lead to the shift of clindamycin distribution away from the surface and promote the local diffusion of clindamycin near the pore surface. The information in this work will provide the microscopic understanding for the design of the drug carriers for the controlled release of clindamycin.